Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 4/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377294 | 0.86 | SLC1A3 (0.45) | PPARGDHODHSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12377309 | 0.86 | PRCP (0.43) | PPARGDHODHSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12377293 | 0.84 | PRCP (0.38) | PDE2ASLC1A3SLC1A2SLC1A1TTK | |
| SCHEMBL12377279 | 0.78 | HSD17B10 (0.55) | DHODHHDAC6LMNA | |
| SCHEMBL12413915 | 0.76 | SLC1A3 (0.44) | DHODHSLC1A3SLC1A2SLC1A1HDAC6 | |
| SCHEMBL12413905 | 0.76 | PRCP (0.42) | DHODHSLC1A3SLC1A2SLC1A1IRAK4 | |
| SCHEMBL12377324 | 0.76 | MAPT (0.52) | LMNA | |
| SCHEMBL5087662 | 0.73 | NPC1 (0.51) | IRAK4 | |
| SCHEMBL14641727 | 0.73 | SLC1A3 (0.42) | DHODHSLC1A3SLC1A2SLC1A1HDAC6 | |
| SCHEMBL12377303 | 0.71 | PRCP (0.47) | SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989422-B2 | Antibacterial agents | ALCHEMIA LIMITED (AU) | 2011-08-02 | — | — | US | disclosed |
| US-7989422-B2 | Antibacterial agents | ALCHEMIA LIMITED (AU) | 2011-08-02 | — | — | US | disclosed |
| US-20090023669-A1 | Antibacterial Agents | ALCHEMIA LIMITED (AU) | 2009-01-22 | — | — | US | disclosed |
| US-20090023669-A1 | Antibacterial Agents | ALCHEMIA LIMITED (AU) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023669-A1 | Antibacterial Agents | MRPL21, FUT6, FUT5 | PPARG 4215/4885PDE2A 2984/4885DHODH 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.